Twinbeech Capital LP Buys New Position in Kenvue Inc. (NYSE:KVUE)

Twinbeech Capital LP bought a new stake in Kenvue Inc. (NYSE:KVUE - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,940,810 shares of the company's stock, valued at approximately $41,436,000. Twinbeech Capital LP owned about 0.10% of Kenvue as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the company. Kiley Juergens Wealth Management LLC grew its holdings in Kenvue by 1.9% in the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company's stock valued at $579,000 after purchasing an additional 500 shares during the last quarter. Principle Wealth Partners LLC boosted its stake in shares of Kenvue by 3.7% during the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company's stock valued at $303,000 after acquiring an additional 500 shares during the last quarter. White Pine Capital LLC boosted its stake in shares of Kenvue by 1.0% during the fourth quarter. White Pine Capital LLC now owns 54,572 shares of the company's stock valued at $1,165,000 after acquiring an additional 542 shares during the last quarter. Deseret Mutual Benefit Administrators boosted its stake in shares of Kenvue by 29.0% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company's stock valued at $54,000 after acquiring an additional 568 shares during the last quarter. Finally, SRS Capital Advisors Inc. boosted its stake in shares of Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after acquiring an additional 571 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Trading Down 2.1%

NYSE:KVUE traded down $0.52 during mid-day trading on Thursday, reaching $23.49. The company's stock had a trading volume of 13,277,432 shares, compared to its average volume of 16,425,190. The company's fifty day simple moving average is $23.22 and its two-hundred day simple moving average is $22.62. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $25.17. The stock has a market cap of $45.06 billion, a P/E ratio of 44.31, a P/E/G ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. The company had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.69 billion. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The company's quarterly revenue was down 3.9% compared to the same quarter last year. During the same period last year, the business posted $0.28 EPS. On average, equities analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be issued a dividend of $0.205 per share. The ex-dividend date is Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.49%. Kenvue's payout ratio is 149.09%.

Analyst Ratings Changes

A number of research firms recently commented on KVUE. Citigroup increased their price objective on Kenvue from $22.00 to $24.50 and gave the company a "neutral" rating in a research note on Friday, May 9th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Piper Sandler increased their price objective on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Canaccord Genuity Group increased their price objective on Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Finally, Barclays increased their price objective on Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research note on Monday, May 12th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Kenvue currently has a consensus rating of "Hold" and a consensus price target of $25.33.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.